Thermo Fisher Scientific brings its expertise to CPHI Frankfurt 2022

CPHI Frankfurt 2022 is now upon us, and Thermo Fisher Scientific is making a splash. 

Thermo Fisher operates across many areas of expertise including in cell and gene therapy, oral solids, steriles, and biologics. They are hoping their solutions will assist companies in getting their products to market in a faster, safer way. 

"As pharma and biotechs look to transform molecules to medicines, they are looking for integrated solutions that connect the entire value chain from early development and clinical trials to scalable manufacturing and integrated sourcing," stated Leon Wyszkowski, President of commercial operations, pharma services, Thermo Fisher Scientific. “This week, we will demonstrate our deep expertise across a range of topics — from clinical research and advanced therapies to digital technologies — to help our customers accelerate their innovation and speed the delivery of breakthrough medicines and therapies to patients.” 
  
Thermo Fisher will be hosting several sessions whilst at CPHI Frankfurt, details which can be found below: 

CPHI Frankfurt Expert Live Sessions  
On November 1 and 2, Thermo Fisher’s experts will participate in several sessions, including: 
•    Keynote: Delivering on the Promise of Cell and Gene Therapy, A Patient-Centric Approach, Panteli Theocharous, Ph.D., FRCPath, global vice president, cell and gene therapy strategy lead, clinical research, Thermo Fisher, November 1, 14.00-14.30 CET 
•    The Impact of M&A in the Pharma and CDMO Community, Anil Kane, Ph.D., global head of technical and scientific affairs, pharma services, Thermo Fisher, November 1, 14.40-15.30 CET 
•    Enabling a Digital Culture through Integrated Business Processes, Sara Sheriff, vice president of integration/engineering operations, pharma services, Thermo Fisher, November 2, 11.20 - 11.45 CET 
For more about Thermo Fisher sessions and activities at CPHl Frankfurt, please visit here. 

Thermo Fisher have been expanding to meet demand for services with the recent opening of a new viral vector manufacturing facility in Plainville, MA, USA. The sustainably built facility houses laboratory and production suites, warehouses, office space and importantly, the company’s bioproduction and analytical instrumentation technologies. By combining the production process in one facility means the supply chain is more sustainable and efficient, accelerating the journey for viral vector products to reach the clinic. Thermo Fisher have partnered with Patheon Commercial Packaging Services for Cell and Gene Therapies to tackle speciality packaging needs and effectively cover all stages in the supply chain. 

Further cGMP manufacturing facilities have been opened in California and Florida, USA, Hangzhou, China, and in Lengnau, Switzerland, covering aspects of cell therapy and biologics development. 

Thermo Fisher are also developing digitally, with hopes of driving digital transformations throughout the drug development and manufacturing processes. The development of their digital platform, Pharma 4.0, enables customers to see the whole process from ordering to production to forecasting. 

Thermo Fisher experts will be available at CPHI Frankfurt 2022 at Booth #90J10, Hall 9 if you would to find out more!